Long-term outcome of budesonide middle meatus treatment for chronic rhinosinusitis patients following endoscopic sinus surgery.
- Author:
Xiaodong CHEN
;
Haiting WANG
;
Zhaohui SHI
;
Xiaoyuan LI
;
Boyi SHAN
;
Tao XUE
;
Li QIAO
;
Fuquan CHEN
- Publication Type:Journal Article
- MeSH:
Budesonide;
therapeutic use;
Chronic Disease;
Endoscopy;
Humans;
Nose;
Paranasal Sinuses;
surgery;
Postoperative Period;
Rhinitis;
drug therapy;
Sinusitis;
drug therapy
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2016;30(3):203-208
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the long term clinical effect of budesonide treatment in middle meatus for chronic rhinosinusitis(CRS) following endoscopic sinus surgery (ESS).
METHOD:A total number of 53 patients with CRS received ESS were divided into two groups according to budesonide treatment: budesonide-treated group with 21 cases (39.6%) and control group with 32 cases (60.4%). Gelatin sponges soaked with 1 ml budesonide suspension were put in middle meatus in budesonide-treated group, while only gelatin sponges were put in middle meatus in control group. Visual analogy score (VAS), sino-nasal outcome test-22 (SNOT-22) and Lund-Kennedy endoscopic scale were carried out before ESS and two years after ESS.
RESULT:In budesonide-treated group, there were a statistical difference before and after ESS in the VAS, SNOT-20 and Lund-Kennedy score (P<. 05). In control group, difference was also significant in VAS, SNOT-20 and Lund-Kennedy score before and after ESS (P < 0.05). The VAS gap of post-operative and pre-operative in two groups are significantly different (P<. 05). However, there was no significant difference in the SNOT-20 and Lund-Kennedy endoscopic scale gap before or after the operation between two groups.
CONCLUSION:It is safe, convenient and practicable to perform budesonide treatment in middle meatus following ESS, which can significantly ease the post-operative discomfort of nose.
